• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 243

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

Manvir Singh: Shamanism, the Timeless Religion

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year...

Wesana Health Partners with University of South Carolina

Albert Labs Announces a Distinguished Clinical and Scientific Advisory Board

Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief...

Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has...

Exclusively-Natural Psychedelic Pharma Company, Filament Health, Lists on the NEO Exchange

Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production...

Silo Wellness Debuts Marley One, the First Global Functional and Psychedelic...

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic...

Book Review: Alexander Shulgin’s The Nature of Drugs

1...242243244...305Page 243 of 305

EDITOR PICKS

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to...

Psychedelic Medicine at the Edge of Science and Spirit

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©